Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase AKT1]
Substrate: AR

Description: Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptorsubfamily 3 group C member 4).

Synonyms: DHTR, NR3C4

Ensembl ID: ENSG00000169083

UniprotKB/SwissProt: ANDR_HUMAN (P10275)

Function: The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Activated, but not phosphorylated, by HIPK3.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Nucleus.
PDB:1E3G
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of AR

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1ARANDR_HUMANS16YPRPP S KTYRG 40.07% HPRD:02437(in vitro)View   
2ARANDR_HUMANS16YPRPP S KTYRG 40.07% Phospho.ELM 7.0View   
3ARANDR_HUMANS81QQQET S PRQQQ 19.82% Phospho.ELM 7.0View   
4ARANDR_HUMANS81QQQET S PRQQQ 19.82% HPRD:02437(in vitro)View   
5ARANDR_HUMANS94QGEDG S PQAHR 26.59% Phospho.ELM 7.0View   
6ARANDR_HUMANS94QGEDG S PQAHR 26.59% HPRD:02437(in vitro)View   
7ARANDR_HUMANS119PSQPQ S ALECH 41.31% HPRD:02437(in vitro)View   
8ARANDR_HUMANS206SEGSS S GRARE 33.71%AKT1 HPRD:02437(in vitro;in vivo)  ViewAnalyzing
9ARANDR_HUMANS213RAREA S GAPTS 30.63%AKT_group Phospho.ELM 7.0 ViewAnalyzing
10ARANDR_HUMANS213RAREA S GAPTS 30.63%AKT1 HPRD:02437(in vitro;in vivo)  ViewAnalyzing
11ARANDR_HUMANY223SSKDN Y LGGTS 19.50%CSK Swiss-Prot 55.0   ViewAnalyzing
12ARANDR_HUMANS256ALEHL S PGEQL 32.54% HPRD:02437(in vitro)View   
13ARANDR_HUMANS256ALEHL S PGEQL 32.54% Phospho.ELM 7.0View   
14ARANDR_HUMANY267RGDCM Y APLLG 16.05%CSK Swiss-Prot 55.0   ViewAnalyzing
15ARANDR_HUMANS300DSAGK S TEDTA 35.79% HPRD:02437(in vitro)View   
16ARANDR_HUMANY307EDTAE Y SPFKG 21.12%CSK Swiss-Prot 55.0   ViewAnalyzing
17ARANDR_HUMANS308DTAEY S PFKGG 18.50% HPRD:02437(in vitro)View   
18ARANDR_HUMANS308DTAEY S PFKGG 18.50% Phospho.ELM 7.0View   
19ARANDR_HUMANY346STLSL Y KSGAL 10.34%CSK Swiss-Prot 55.0   ViewAnalyzing
20ARANDR_HUMANY357DEAAA Y QSRDY 11.42%CSK Swiss-Prot 55.0   ViewAnalyzing
21ARANDR_HUMANY362YQSRD Y YNFPL 10.13%CSK Swiss-Prot 55.0   ViewAnalyzing
22ARANDR_HUMANY363QSRDY Y NFPLA 18.02%CSK Swiss-Prot 55.0   ViewAnalyzing
23ARANDR_HUMANY393ENPLD Y GSAWA 22.21%CSK Swiss-Prot 55.0   ViewAnalyzing
24ARANDR_HUMANS424GPGSG S PSAAA 19.85% HPRD:02437(in vitro)View   
25ARANDR_HUMANS424GPGSG S PSAAA 19.85% Phospho.ELM 7.0View   
26ARANDR_HUMANS515RVPYP S PTCVK 27.31% Phospho.ELM 7.0View   
27ARANDR_HUMANY534SYSGP Y GDMRL 29.32%CSK Swiss-Prot 55.0   ViewAnalyzing
28ARANDR_HUMANY551VLPID Y YFPPQ 14.02%CSK Swiss-Prot 55.0   ViewAnalyzing
29ARANDR_HUMANS650ASSTT S PTEET 29.88% HPRD:02437(in vitro)View   
30ARANDR_HUMANS650ASSTT S PTEET 29.88% Phospho.ELM 7.0View   
31ARANDR_HUMANS791RMRHL S QEFGW 22.87%AKT_group Phospho.ELM 7.0 ViewAnalyzing
32ARANDR_HUMANS791RMRHL S QEFGW 22.87%AKT1 HPRD:02437(in vitro)  ViewAnalyzing
33ARANDR_HUMANY915KVKPI Y FHTQ 9.61%CSK Swiss-Prot 55.0   ViewAnalyzing